
GlaxoSmithKline plc GSK
$ 57.54
-0.47%
Annual report 2025
added 04-04-2026
GlaxoSmithKline plc Operating Cycle 2011-2026 | GSK
Annual Operating Cycle GlaxoSmithKline plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 0.02 | 0.04 | 0.04 | 0.08 | 0.06 | 200 | 194 | 211 | 166 | 184 | 193 |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 211 | 0.02 | 104 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
102 | $ 327.75 | -1.69 % | $ 42.9 B | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
237 | $ 21.62 | -0.28 % | $ 1.01 B | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Akebia Therapeutics
AKBA
|
210 | $ 1.41 | -9.03 % | $ 363 M | ||
|
Aquestive Therapeutics
AQST
|
223 | $ 4.18 | -1.5 % | $ 447 M | ||
|
Arcutis Biotherapeutics
ARQT
|
291 | $ 24.23 | -1.42 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | ||
|
Grifols, S.A.
GRFS
|
0.000171 | $ 8.68 | -0.12 % | $ 6.83 B | ||
|
Autolus Therapeutics plc
AUTL
|
129 | $ 1.48 | -0.67 % | $ 394 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | ||
|
Clearside Biomedical
CLSD
|
61.7 | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
321 | $ 33.44 | -1.27 % | $ 2.22 B | ||
|
bluebird bio
BLUE
|
127 | - | - | $ 546 M |